|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRTO4 |
Gene summary for MRTO4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRTO4 | Gene ID | 51154 |
| Gene name | MRT4 homolog, ribosome maturation factor | |
| Gene Alias | C1orf33 | |
| Cytomap | 1p36.13 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | A0A024RAE1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51154 | MRTO4 | LZE4T | Human | Esophagus | ESCC | 2.26e-08 | 8.08e-02 | 0.0811 |
| 51154 | MRTO4 | LZE7T | Human | Esophagus | ESCC | 1.78e-09 | 3.50e-01 | 0.0667 |
| 51154 | MRTO4 | LZE8T | Human | Esophagus | ESCC | 9.48e-06 | 1.58e-01 | 0.067 |
| 51154 | MRTO4 | LZE22T | Human | Esophagus | ESCC | 3.75e-02 | 5.78e-01 | 0.068 |
| 51154 | MRTO4 | LZE24T | Human | Esophagus | ESCC | 2.42e-12 | 2.51e-01 | 0.0596 |
| 51154 | MRTO4 | LZE21T | Human | Esophagus | ESCC | 6.31e-03 | 2.09e-01 | 0.0655 |
| 51154 | MRTO4 | P1T-E | Human | Esophagus | ESCC | 2.40e-15 | 4.43e-01 | 0.0875 |
| 51154 | MRTO4 | P2T-E | Human | Esophagus | ESCC | 1.06e-37 | 9.07e-01 | 0.1177 |
| 51154 | MRTO4 | P4T-E | Human | Esophagus | ESCC | 3.43e-20 | 6.46e-01 | 0.1323 |
| 51154 | MRTO4 | P5T-E | Human | Esophagus | ESCC | 9.06e-20 | 4.45e-01 | 0.1327 |
| 51154 | MRTO4 | P8T-E | Human | Esophagus | ESCC | 2.62e-19 | 3.16e-01 | 0.0889 |
| 51154 | MRTO4 | P9T-E | Human | Esophagus | ESCC | 1.87e-18 | 4.23e-01 | 0.1131 |
| 51154 | MRTO4 | P10T-E | Human | Esophagus | ESCC | 8.56e-36 | 6.34e-01 | 0.116 |
| 51154 | MRTO4 | P11T-E | Human | Esophagus | ESCC | 2.08e-14 | 4.96e-01 | 0.1426 |
| 51154 | MRTO4 | P12T-E | Human | Esophagus | ESCC | 1.41e-17 | 4.33e-01 | 0.1122 |
| 51154 | MRTO4 | P15T-E | Human | Esophagus | ESCC | 9.45e-30 | 6.52e-01 | 0.1149 |
| 51154 | MRTO4 | P16T-E | Human | Esophagus | ESCC | 9.46e-24 | 4.55e-01 | 0.1153 |
| 51154 | MRTO4 | P17T-E | Human | Esophagus | ESCC | 3.56e-11 | 6.75e-01 | 0.1278 |
| 51154 | MRTO4 | P19T-E | Human | Esophagus | ESCC | 4.43e-06 | 1.00e+00 | 0.1662 |
| 51154 | MRTO4 | P20T-E | Human | Esophagus | ESCC | 6.08e-21 | 5.82e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:0000027111 | Esophagus | ESCC | ribosomal large subunit assembly | 22/8552 | 27/18723 | 1.49e-04 | 9.92e-04 | 22 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRTO4 | SNV | Missense_Mutation | rs748671029 | c.481N>A | p.Ala161Thr | p.A161T | Q9UKD2 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
| MRTO4 | insertion | In_Frame_Ins | novel | c.174_175insCATTTA | p.Asn58_Ala59insHisLeu | p.N58_A59insHL | Q9UKD2 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MRTO4 | insertion | Frame_Shift_Ins | novel | c.175_176insATTGGTCTCTCATCATCTCTCT | p.Ala59AspfsTer32 | p.A59Dfs*32 | Q9UKD2 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MRTO4 | SNV | Missense_Mutation | c.140A>G | p.Asn47Ser | p.N47S | Q9UKD2 | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-AH-6897-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MRTO4 | SNV | Missense_Mutation | rs564605284 | c.635N>T | p.Ser212Leu | p.S212L | Q9UKD2 | protein_coding | tolerated(0.19) | benign(0.009) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRTO4 | SNV | Missense_Mutation | novel | c.162N>T | p.Lys54Asn | p.K54N | Q9UKD2 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MRTO4 | SNV | Missense_Mutation | rs754307809 | c.565N>A | p.Val189Ile | p.V189I | Q9UKD2 | protein_coding | tolerated(1) | benign(0) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRTO4 | SNV | Missense_Mutation | rs563261309 | c.190C>T | p.Arg64Trp | p.R64W | Q9UKD2 | protein_coding | deleterious(0.01) | possibly_damaging(0.563) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRTO4 | SNV | Missense_Mutation | c.62N>G | p.Glu21Gly | p.E21G | Q9UKD2 | protein_coding | tolerated(0.07) | benign(0.33) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MRTO4 | SNV | Missense_Mutation | rs769660709 | c.169N>T | p.Arg57Trp | p.R57W | Q9UKD2 | protein_coding | deleterious(0.01) | possibly_damaging(0.825) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |